Cell line development

High-yield, high quality research and manufacturing cell lines

Polpharma Biologics have over 25 years of success in generating high-yield production cell lines for innovative proteins.

Our proprietary CHO^BC® expression platform allows rapid generation of high-quality cell lines with a completely animal component-free (ACF) process.

Developing high quality, high titer manufacturing cell lines with CHO^BC®

Polpharma Biologics generate high-yield, high quality production research and manufacturing cell lines for innovative proteins. High-throughput technologies are deployed to increase productivity and achieve the highest titers possible, while minimizing undesired species.

We can also rapidly scale to 50 L production for early stage material or transfer to our manufacturing stream for process development and 50 – 2000 L cGMP production.

Our CHO^BC® expression platform combines the following features:

CHO-K1 derived suspension cell line
Allows rapid generation of high-quality cell lines
Completely animal component-free (ACF) process
Grown in chemically defined media
High-throughput technologies are deployed to increase productivity and achieve the highest titers possible, while minimizing undesired species
Research cell banks are rigorously tested for the absence of viral elements in accordance with ICH guidelines
CHO^BC® cell lines have already been successfully scaled-up to 1,000 L and used to produce drug substance for clinical trial supply.
Competitive timelines from DNA to research cell bank
Quick scale up to 50 L for pre-clinical supply
Combine with our master cell banking, process development and manufacturing services for a fast route to IND

Integrated technologies to improve process efficiency and enhance expression

SLIM™ technology improves process efficiency and allows for further process optimization

Our Scientific Leverage of Innovative Metabolism (SLIM™) technology reduces feed consumption at much lower power input eliminating hardware limitations in upstream development, reducing the cost of development.

Enhance expression with SPOT™ technology to deliver up to 9 g/L

Our CHO^BC® cell line delivers good tires as standard from 2-4 g/L but we have developed our SPOT™ (Specific Productivity Optimization Technology) which increases cell size and specific expression of the desired protein without increasing the amount of host cell protein or other undesired excipients. This significantly reduces downstream costs due to easier purification.

titer (g/L)

250%

150%

190%

180%

570%

Biologic 1

SPOT™ Biologic 1

Biologic 2

SPOT™ Biologic 2

Biologic 3

SPOT™ Biologic 3

biologic 4

SPOT™ Biologic 4

SPOT™ + SLIM™ Biologic 4

Biologic 5

SPOT™ Biologic 5

SPOT™ + SLIM™ Biologic 5

Biologic 6

SPOT™ Biologic 6

Specific productivity increases seen once SPOT™ technology has been applied to CHO^BC® cell lines. Titer increases from 150 to 300% are regularly observed.

Accessing CHO^BC®, SLIM™ and SPOT™ Technology

“We are committed to positive outcomes and delivering projects on time to specification”

Polpharma Biologics offer their cell line development packages on a fee for service basis, this can either be as a stand alone cell line development project or as part of an integrated Idea to IND package. We can also work on improving your current cell lines productivity with our SLIM™ or SPOT™ technology.